Skip to main content
SpringerLink
Log in

Nanotechnology-Based Cancer Vaccine

  • Protocol
  • First Online:
Cancer Nanotechnology

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1530))

Abstract

Nanotechnology offers invaluable tools to tailor cancer vaccines in order to generate robust antitumor immune response. Among the types of vehicles for cancer vaccines, nanoparticles (NPs) are easier to produce with better scalability. Several nanostructures have been discussed in literature as potential delivery systems for cancer antigens. Here, we focus on polymeric NPs fabricated from poly(d,l-lactic-co-glycolic) acid (PLGA). We describe how to prepare and characterize such NPs loaded with ovalbumin (OVA) antigen and immune adjuvant monophosphoryl lipid A (MPLA). We further describe methods to test the immune efficacy of such NPs in vitro and in vivo.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Schuster M, Nechansky A, Kircheis R (2006) Cancer immunotherapy. Biotechnol J 1(2):138–147. doi:10.1002/biot.200500044

    Article  CAS  PubMed  Google Scholar 

  2. Hamdy S, Alshamsan A, Samuel J (2009) Nanotechnology for cancer vaccine delivery, Nanotechnology in drug delivery. Springer, New York, pp 519–543

    Google Scholar 

  3. Bolhassani A, Safaiyan S, Rafati S (2011) Improvement of different vaccine delivery systems for cancer therapy. Mol Cancer 10:3. doi:10.1186/1476-4598-10-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Fan Y, Moon JJ (2015) Nanoparticle drug delivery systems designed to improve cancer vaccines and immunotherapy. Vaccines 3(3):662–685. doi:10.3390/vaccines3030662

    Article  PubMed  PubMed Central  Google Scholar 

  5. Li W, Wei H, Li H, Gao J, Feng SS, Guo Y (2014) Cancer nanoimmunotherapy using advanced pharmaceutical nanotechnology. Nanomedicine 9(16):2587–2605. doi:10.2217/nnm.14.127

    Article  CAS  PubMed  Google Scholar 

  6. Hamdy S, Haddadi A, Hung RW, Lavasanifar A (2011) Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv Drug Deliv Rev 63(10–11):943–955. doi:10.1016/j.addr.2011.05.021

    Article  CAS  PubMed  Google Scholar 

  7. Elamanchili P, Lutsiak CM, Hamdy S, Diwan M, Samuel J (2007) “Pathogen-mimicking” nanoparticles for vaccine delivery to dendritic cells. J Immunother 30(4):378–395. doi:10.1097/CJI.0b013e31802cf3e3

    Article  CAS  PubMed  Google Scholar 

  8. Ali OA, Huebsch N, Cao L, Dranoff G, Mooney DJ (2009) Infection-mimicking materials to program dendritic cells in situ. Nat Mater 8(2):151–158. doi:10.1038/nmat2357

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, Schuler G (1999) An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223(1):77–92

    Article  CAS  PubMed  Google Scholar 

  10. Hamdy S, Elamanchili P, Alshamsan A, Molavi O, Satou T, Samuel J (2007) Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D, L-lactic-co-glycolic acid) nanoparticles. J Biomed Mater Res A 81(3):652–662. doi:10.1002/jbm.a.31019

    Article  PubMed  Google Scholar 

  11. Hamdy S, Molavi O, Ma Z, Haddadi A, Alshamsan A, Gobti Z, Elhasi S, Samuel J, Lavasanifar A (2008) Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine 26(39):5046–5057. doi:10.1016/j.vaccine.2008.07.035

    Article  CAS  PubMed  Google Scholar 

  12. Weinstein Y, Ran S, Segal S (1984) Sex-associated differences in the regulation of immune responses controlled by the MHC of the mouse. J Immunol 132(2):656–661

    CAS  PubMed  Google Scholar 

  13. Kishimoto S, Tsuyuguchi I, Yamamura Y (1969) Immune responses in aged mice. Clin Exp Immunol 5(5):525–530

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65(1–2):55–63

    Article  CAS  PubMed  Google Scholar 

  15. Riss TL, Moravec RA, Niles AL, Benink HA, Worzella TJ, Minor L (2004) Cell viability assays. In: Sittampalam GS, Coussens NP, Nelson H et al (eds) Assay guidance manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda, MD

    Google Scholar 

Download references

Acknowledgment

This work was supported by King Abdullah Institute for Nanotechnology and the Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia.

Author information

Authors and Affiliations

  1. Nanomedicine Research Unit, Department of Pharmaceutics, College of Pharmacy, King Saud University, 2457, Riyadh, 11451, Saudi Arabia

    Aws Alshamsan

  2. King Abdullah Institute for Nanotechnology, King Saud University, 2455, Riyadh, 11451, Saudi Arabia

    Aws Alshamsan

Authors
  1. Aws Alshamsan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aws Alshamsan .

Editor information

Editors and Affiliations

  1. School of Applied Sciences, Mount Ida College, Newton, Massachusetts, USA

    Reema Zeineldin

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media New York

About this protocol

Cite this protocol

Alshamsan, A. (2017). Nanotechnology-Based Cancer Vaccine. In: Zeineldin, R. (eds) Cancer Nanotechnology. Methods in Molecular Biology, vol 1530. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6646-2_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-6646-2_15

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-6644-8

  • Online ISBN: 978-1-4939-6646-2

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation